康弘药业：收到布瑞哌唑片的药品注册证书

Core Viewpoint - Kanghong Pharmaceutical has received the drug registration certificate for Brexpiprazole tablets from the National Medical Products Administration, which is approved for the treatment of adult schizophrenia, enhancing the company's product pipeline [1] Group 1 - The drug is classified as a Class 4 chemical drug [1] - The approval of Brexpiprazole tablets adds to the company's product offerings [1] - The production and sales of pharmaceutical products may be influenced by changes in the market environment, leading to uncertainties [1]